Drug Patents owned by Pfizer
1. Drug name - CIBINQO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
| US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
| CN105008362B | PFIZER | As Associated Janus Kinase (Jak) Inhibitor Of Pyrrolo [2 3-D] Pyrimidine Derivatives |
Feb, 2034
(11 years from now) | |
| CN105008362A | PFIZER | Pyrrolo [2, 3-D] Pyrimidine Derivative Used As James Related Kinase (As Jak) Inhibitor |
Feb, 2034
(11 years from now) | |
| CN107089985B | PFIZER | As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives |
Feb, 2034
(11 years from now) | |
| CN107089985A | PFIZER | As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives |
Feb, 2034
(11 years from now) | |
| IN201506803P1 | PFIZER | Pyrrolo [2 3 D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak) |
Feb, 2034
(11 years from now) | |
| IN329290B | PFIZER | Pyrrolo [2, 3, D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak) |
Feb, 2034
(11 years from now) | |
| EP3290421B1 | PFIZER | Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak) |
Feb, 2034
(11 years from now) | |
| EP3290421A1 | PFIZER | Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak) |
Feb, 2034
(11 years from now) | |
| EP2958921A1 | PFIZER | Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak) |
Feb, 2034
(11 years from now) | |
| EP2958921B1 | PFIZER | Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak) |
Feb, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(11 years from now) | |
Drugs and Companies using ABROCITINIB ingredient
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
| 200MG | TABLET;ORAL | Prescription |
2. Drug name - DAURISMO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8148401 | PFIZER | Benzimidazole derivatives |
Jan, 2031
(8 years from now) | |
| US10414748 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(13 years from now) | |
| CN101687841B | PFIZER | Benzimidazole Derivatives |
Jun, 2028
(5 years from now) | |
| CN101687841A | PFIZER | Benzimidazole Derivatives |
Jun, 2028
(5 years from now) | |
| IN288288B | PFIZER | A Compound That Is 1-[(2R,4R)-2-(1Hbenzimidazol- 2-Yl)- 1-Methyl-Piperidin- 4-Yl]-3-(4- Cyanophenyl)Urea Or A Pharmaceutically Acceptable Salt Thereof |
Jun, 2028
(5 years from now) | |
| IN200908059P1 | PFIZER | Benzimidazole Derivatives |
Jun, 2028
(5 years from now) | |
| EP2170860B9 | PFIZER | Benzimidazole Derivatives |
Jun, 2028
(5 years from now) | |
| EP2170860B1 | PFIZER | Benzimidazole Derivatives |
Jun, 2028
(5 years from now) | |
| EP2170860A2 | PFIZER | Benzimidazole Derivatives |
Jun, 2028
(5 years from now) | |
| EP3666768A1 | PFIZER | Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1) |
Apr, 2036
(13 years from now) | |
| EP3666768B1 | PFIZER | Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1) |
Apr, 2036
(13 years from now) | |
| EP3286176B1 | PFIZER | Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate |
Apr, 2036
(13 years from now) | |
| EP3286176A1 | PFIZER | Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate |
Apr, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(5 years from now) | |
| US11168066 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(13 years from now) | |
Drugs and Companies using GLASDEGIB MALEATE ingredient
Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 25MG BASE | TABLET;ORAL | Prescription |
| EQ 100MG BASE | TABLET;ORAL | Prescription |
3. Drug name - IBRANCE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6936612 | PFIZER | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
Jan, 2023
(3 months from now) | |
| US7208489 | PFIZER | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
Jan, 2023
(3 months from now) | |
| USRE47739 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
Mar, 2027
(4 years from now) | |
| US10723730 | PFIZER | Solid forms of a selective CDK4/6 inhibitor |
Feb, 2034
(11 years from now) | |
| CN105008357A | PFIZER | Solid State Form Of Selective Cdk4/6 Inhibitor |
Jul, 2020
(2 years ago) | |
| CN101906104B | PFIZER | 2-(Pyridin-2-Yl Amino)-Pyrido [2, 3-D] Pyrimidin-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN101001857A | PFIZER | 2-(Pyridine-2-Yl Amido)-Pyridino[2,3-D]Pyrimidine-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN102295643B | PFIZER | 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN101906104A | PFIZER | 2-(Pyrid-2-Ylamino)-Pyridino[2,3-D] Pyrimidine-7-One |
Jan, 2023
(3 months from now) | |
| CN102295643A | PFIZER | 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone |
Jan, 2023
(3 months from now) | |
| CN101001857B | PFIZER | 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone |
Jan, 2023
(3 months from now) | |
| IN218291B | PFIZER | 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones |
Jan, 2023
(3 months from now) | |
| IN200401733P1 | PFIZER | 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones |
Jan, 2023
(3 months from now) | |
| EP1470124B1 | PFIZER | 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D Pyrimidin-7-Ones |
Jan, 2023
(3 months from now) | |
| EP1470124A1 | PFIZER | 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D]Pyrimidin-7-Ones |
Jan, 2023
(3 months from now) | |
| EP2958916A1 | PFIZER | Solid Forms Of A Selective Cdk4/6 Inhibitor |
Feb, 2034
(11 years from now) | |
| EP3431475B1 | PFIZER | Solid Forms Of A Selective Cdk4/6 Inhibitor |
Feb, 2034
(11 years from now) | |
| EP3431475A1 | PFIZER | Solid Forms Of A Selective Cdk4/6 Inhibitor |
Feb, 2034
(11 years from now) | |
| EP2958916B1 | PFIZER | Solid Forms Of A Selective Cdk4/6 Inhibitor |
Feb, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7456168 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
Jan, 2023
(3 months from now) | |
| US11065250 | PFIZER | Solid dosage forms of palbociclib |
May, 2036
(13 years from now) | |
Drugs and Companies using PALBOCICLIB ingredient
Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 75MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
| 125MG | TABLET;ORAL | Prescription |
4. Drug name - LORBRENA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(10 years from now) | |
| US10420749 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
| CN104169286A | PFIZER | Macrocyclic Derivative For Treating Proliferative Diseases |
Feb, 2033
(10 years from now) | |
| CN104169286B | PFIZER | Macrocyclic Derivative For Treating Proliferative Diseases |
Feb, 2033
(10 years from now) | |
| IN201407205P4 | PFIZER | Macrocyclic Derivatives For The Treatment Of Proliferative Diseases |
Feb, 2033
(10 years from now) | |
| IN298989B | PFIZER | Macrocyclic Derivatives For The Treatment Of Proliferative Diseases |
Feb, 2033
(10 years from now) | |
| EP2822953B9 | PFIZER | Macrocyclic Derivatives For The Treatment Of Proliferative Diseases |
Feb, 2033
(10 years from now) | |
| EP2822953B1 | PFIZER | Macrocyclic Derivatives For The Treatment Of Proliferative Diseases |
Feb, 2033
(10 years from now) | |
| EP2822953A1 | PFIZER | Macrocyclic Derivatives For The Treatment Of Proliferative Diseases |
Feb, 2033
(10 years from now) | |
| EP3328867B9 | PFIZER | Crystalline Form Of Lorlatinib Free Base |
Jul, 2036
(13 years from now) | |
| EP3328867A1 | PFIZER | Crystalline Form Of Lorlatinib Free Base |
Jul, 2036
(13 years from now) | |
| EP3328867B1 | PFIZER | Crystalline Form Of Lorlatinib Free Base |
Jul, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020376 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 25MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
5. Drug name - TALZENNA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8420650 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(6 years from now) | |
| US8012976 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Oct, 2029
(7 years from now) | |
| US10189837 | PFIZER | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
Oct, 2031
(9 years from now) | |
| US8735392 | PFIZER | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
Oct, 2031
(9 years from now) | |
| CN104478875B | PFIZER | Poly (Adp-Ribose) Polymerase (Parp) Dihydropyridine And Phthalazinone Inhibitors |
Jul, 2029
(6 years from now) | |
| CN102171214A | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| CN102171214B | PFIZER | Poly (Adp-Ribose) Polymerase (Parp) And Dihydro Pyridine Phthalocyanine And Triazine Ketone Inhibitor |
Jul, 2029
(6 years from now) | |
| CN104478875A | PFIZER | Dihydro Pyridine Phthalocyanine Triazine Ketone Inhibitor Of Poly (Adp-Ribose) Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| CN103282365A | PFIZER | Crystals Of (8S, 9R) -5-(4 - (-8 - Fluorophenyl) -9-(1-Methyl - -1H-1, 2, 4-Triazole - -5 - Group) - 9, -8 - Dihydro - -2H - Pyrido [4 3, 2-De] Phthalazine -3 (7H) - Ketone Tosylate |
Oct, 2031
(9 years from now) | |
| CN103282365B | PFIZER | Crystalline Toluenesulfonate Of (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phthalazine-3-(7H)-One |
Oct, 2031
(9 years from now) | |
| IN298469B | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adpribose) Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2326650A2 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2326650B1 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2326650B9 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2326650A4 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2767537A1 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2767537B1 | PFIZER | Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp) |
Jul, 2029
(6 years from now) | |
| EP2630146A1 | PFIZER | Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt |
Oct, 2031
(9 years from now) | |
| EP2630146B1 | PFIZER | Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt |
Oct, 2031
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9820985 | PFIZER | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
Jul, 2029
(6 years from now) | |
Drugs and Companies using TALAZOPARIB TOSYLATE ingredient
Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.25MG BASE | CAPSULE;ORAL | Prescription |
| EQ 0.5MG BASE | CAPSULE;ORAL | Prescription |
| EQ 0.75MG BASE | CAPSULE;ORAL | Prescription |
| EQ 1MG BASE | CAPSULE;ORAL | Prescription |
6. Drug name - TOVIAZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(2 months ago) | |
| CN1215045C | PFIZER | Stable Salts Of New Derivatives Of 3, 3-Diphenyl Propylamine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| CN1390194A | PFIZER | Stable Salts Of New Derivatives Of 3, 3-Diphenyl Propylamine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| EP1481964B1 | PFIZER | Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines |
Nov, 2020
(1 year, 10 months ago) | |
| EP1230209B3 | PFIZER | Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines |
Nov, 2020
(1 year, 10 months ago) | |
| EP1690536A3 | PFIZER | Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders |
Nov, 2020
(1 year, 10 months ago) | |
| EP1690536B1 | PFIZER | Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders |
Nov, 2020
(1 year, 10 months ago) | |
| EP1230209B1 | PFIZER | Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines |
Nov, 2020
(1 year, 10 months ago) | |
| EP1230209A2 | PFIZER | Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines |
Nov, 2020
(1 year, 10 months ago) | |
| EP1481964A1 | PFIZER | Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines |
Nov, 2020
(1 year, 10 months ago) | |
| EP1690536A2 | PFIZER | Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders |
Nov, 2020
(1 year, 10 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6858650
(Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(3 months from now) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
|
US7807715
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(5 years from now) | |
|
US8501723
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(5 years from now) | |
|
US8088398
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(5 years from now) | |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 4MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 8MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
7. Drug name - TROXYCA ER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685443 | PFIZER | Sequestering subunit and related compositions and methods |
Jul, 2025
(2 years from now) | |
| US7815934 | PFIZER | Sequestering subunit and related compositions and methods |
Dec, 2027
(5 years from now) | |
Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1.2MG;10MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
| 2.4MG;20MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
| 3.6MG;30MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
| 4.8MG;40MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
| 7.2MG;60MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
| 9.6MG;80MG | CAPSULE, EXTENDED RELEASE;ORAL | Discontinued |
8. Drug name - VIZIMPRO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7772243 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
Aug, 2028
(5 years from now) | |
| CN1972688B | PFIZER | 4-Anilino-Quinazoline-6-Yl-Amide Compound |
Apr, 2025
(2 years from now) | |
| CN1972688A | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides Compounds |
Apr, 2025
(2 years from now) | |
| IN244837B | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides And A Pharmaceutical Composition Comprising The Same |
Apr, 2025
(2 years from now) | |
| IN200606238P1 | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides |
Apr, 2025
(2 years from now) | |
| EP1746999A1 | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides |
Apr, 2025
(2 years from now) | |
| EP1746999B1 | PFIZER | 4-Phenylamino-Quinazolin-6-Yl-Amides |
Apr, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623883 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
May, 2025
(2 years from now) | |
Drugs and Companies using DACOMITINIB ingredient
Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 15MG | TABLET;ORAL | Prescription |
| 30MG | TABLET;ORAL | Prescription |
| 45MG | TABLET;ORAL | Prescription |
9. Drug name - XELJANZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(3 years from now) | |
| CN1195755C | PFIZER | Pyrrolo [2, 3-D] Pyrimidine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| CN1409712A | PFIZER | Pyrrolo [2, 3-D] Pyrimidine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| IN241773B | PFIZER | Pyrrolo[2,3-D] Pyrimidine Compounds |
Nov, 2020
(1 year, 10 months ago) | |
| IN200200588P1 | PFIZER | Pyrrolo[2,3-D] Pyrimidine Compounds |
Nov, 2020
(1 year, 10 months ago) | |
| EP1235830B1 | PFIZER | Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors |
Nov, 2020
(1 year, 10 months ago) | |
| EP1382339B1 | PFIZER | Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives |
Nov, 2020
(1 year, 10 months ago) | |
| EP1235830A2 | PFIZER | Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors |
Nov, 2020
(1 year, 10 months ago) | |
| EP1382339A1 | PFIZER | Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives |
Nov, 2020
(1 year, 10 months ago) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1MG/ML BASE | SOLUTION;ORAL | Prescription |
10. Drug name - XELJANZ XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6965027 | PFIZER | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(5 months from now) | |
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(3 years from now) | |
| CN1195755C | PFIZER | Pyrrolo [2, 3-D] Pyrimidine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| CN1409712A | PFIZER | Pyrrolo [2, 3-D] Pyrimidine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| CN1325498C | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| CN1596257A | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| IN241773B | PFIZER | Pyrrolo[2,3-D] Pyrimidine Compounds |
Nov, 2020
(1 year, 10 months ago) | |
| IN200200588P1 | PFIZER | Pyrrolo[2,3-D] Pyrimidine Compounds |
Nov, 2020
(1 year, 10 months ago) | |
| IN200401095P1 | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| IN218212B | PFIZER | Crystalline 3-{(3R,4R)-4-Methyl-3-[Methyl-[7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-L-Yl}-3-Oxo-Propinitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| IN200607324P1 | PFIZER | 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| IN251800B | PFIZER | 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| EP1382339A1 | PFIZER | Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives |
Nov, 2020
(1 year, 10 months ago) | |
| EP1235830A2 | PFIZER | Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors |
Nov, 2020
(1 year, 10 months ago) | |
| EP1235830B1 | PFIZER | Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors |
Nov, 2020
(1 year, 10 months ago) | |
| EP1382339B1 | PFIZER | Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives |
Nov, 2020
(1 year, 10 months ago) | |
| EP1451192A1 | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| EP1451192B1 | PFIZER | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) | |
| US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(11 years from now) | |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 11MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 22MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.